TY - JOUR
T1 - Selective metastatic tumor labeling with green fluorescent protein and killing by systemic administration of telomerase-dependent adenoviruses
AU - Kishimoto, Hiroyuki
AU - Urata, Yasuo
AU - Tanaka, Noriaki
AU - Fujiwara, Toshiyoshi
AU - Hoffman, Robert M.
PY - 2009/11
Y1 - 2009/11
N2 - We previously constructed telomerase-dependent, replication-selective adenoviruses OBP-301 (Telomelysin) and OBP-401 [Telomelysin-green fluorescent protein (GFP); TelomeScan], the replication of which is regulated by the human telomerase reverse transcriptase promoter. By intratumoral injection, these viruses could replicate within the primary tumor and subsequent lymph node metastasis. The aim of the present study was to evaluate the possibility of systemic administration of these telomerase-dependent adenoviruses. We assessed the antitumor efficacy of OBP-301 and the ability of OBP-401 to deliver GFP in hepatocellular carcinoma (HCC) and metastatic colon cancer nude mouse models. We showed that i.v. administration of OBP-301 significantly inhibited colon cancer liver metastases and orthotopically implanted HCC. Further, we showed that OBP-401 could visualize liver metastases by tumor-specific expression of the GFP gene after portal venous or i.v. administration. Thus, systemic administration of these adenoviral vectors should have clinical potential to treat and detect liver metastasis and HCC.
AB - We previously constructed telomerase-dependent, replication-selective adenoviruses OBP-301 (Telomelysin) and OBP-401 [Telomelysin-green fluorescent protein (GFP); TelomeScan], the replication of which is regulated by the human telomerase reverse transcriptase promoter. By intratumoral injection, these viruses could replicate within the primary tumor and subsequent lymph node metastasis. The aim of the present study was to evaluate the possibility of systemic administration of these telomerase-dependent adenoviruses. We assessed the antitumor efficacy of OBP-301 and the ability of OBP-401 to deliver GFP in hepatocellular carcinoma (HCC) and metastatic colon cancer nude mouse models. We showed that i.v. administration of OBP-301 significantly inhibited colon cancer liver metastases and orthotopically implanted HCC. Further, we showed that OBP-401 could visualize liver metastases by tumor-specific expression of the GFP gene after portal venous or i.v. administration. Thus, systemic administration of these adenoviral vectors should have clinical potential to treat and detect liver metastasis and HCC.
UR - http://www.scopus.com/inward/record.url?scp=70949102751&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=70949102751&partnerID=8YFLogxK
U2 - 10.1158/1535-7163.MCT-09-0556
DO - 10.1158/1535-7163.MCT-09-0556
M3 - Article
C2 - 19887549
AN - SCOPUS:70949102751
SN - 1535-7163
VL - 8
SP - 3001
EP - 3008
JO - Molecular cancer therapeutics
JF - Molecular cancer therapeutics
IS - 11
ER -